Also trades as: 0JDI.L (LSE) · $vol 0M
IONS NASDAQ
Ionis Pharmaceuticals, Inc.
1W: -3.2%
1M: -3.5%
3M: -18.6%
YTD: -44.8%
1Y: -38.0%
3Y: -4.8%
5Y: +40.5%
$43.96
+0.54 (+1.24%)
After Hours: $43.72 (-0.24, -0.55%)
Weekly Expected Move ±5.4%
$38
$41
$43
$45
$48
Credit Risk of going bust: higher than 52% of companies Debt: 25.1% of company value Bonds: $115.2M held by 65 funds → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.24 (down 97%), Ionis Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $2.42B against a stock market value of $7.22B.
Distance to default 4.94 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.20B (short-term plus half of long-term), stock volatility 44.8%; Altman Z'' 1.30. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.24 (down 97%), Ionis Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $2.42B against a stock market value of $7.22B.
Distance to default 4.94 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.20B (short-term plus half of long-term), stock volatility 44.8%; Altman Z'' 1.30. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
14 relationships14
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2021-12-07
Earliest Filing
2025-03-12
Latest Filing
partner: 8
customer: 3
investor: 2
licensee: 1
Counterparties (Filed by IONS)
14 relationshipsCompanies named in IONS's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Ono Pharmaceutical Co., Ltd. | — | licensee | Ionis Pharmaceuticals granted Ono exclusive global rights to develop and commercialize sapablursen. | 2025-03-12 | View |
| Otsuka Pharmaceutical Co., Ltd. | — | partner | Amended and restated license agreement granting Otsuka exclusive rights to commercialize donidalorsen in the Asia-Pacifi | 2024-06-18 | View |
| Otsuka Pharmaceutical Co., Ltd. | — | partner | Ionis Pharmaceuticals entered into a license agreement granting Otsuka exclusive rights in Europe to commercialize donid | 2023-12-18 | View |
| Novartis Pharma AG | NVSEF | partner | Collaboration and license agreement to discover, develop and commercialize a novel medicine for lipoprotein(a)-driven ca | 2023-08-03 | View |
| Royalty Pharma Investments 2019 ICAV | RPRX | investor | Acquired royalty rights from Ionis Pharmaceuticals and Akcea Therapeutics | 2023-01-09 | View |
| Biogen Idec International Holding Ltd | BIIB | customer | Entity whose net sales generate royalties subject to the royalty purchase agreement | 2023-01-09 | View |
| Biogen MA | BIIB | customer | Entity whose net sales generate royalties subject to the royalty purchase agreement | 2023-01-09 | View |
| Novartis Pharma AG | NVSEF | customer | Entity whose net sales generate royalties subject to the royalty purchase agreement | 2023-01-09 | View |
| Oxford Properties Group | — | partner | Parent company of the Campus Purchaser and BTS Purchaser involved in real estate sale-leaseback transactions | 2022-10-24 | View |
| UBS Commercial Mortgage Trust 2017-C3 | — | investor | Trust issuing commercial mortgage pass-through certificates secured by the loan | 2022-10-24 | View |
| DHC UBSCM 17 C3 Successor Borrower-R, LLC | — | partner | Successor borrower assuming rights and obligations under the mortgage loan documents | 2022-10-24 | View |
| Sudberry Development, Inc. | — | partner | Lease Agreement for construction of a new development chemistry and manufacturing site. | 2022-10-12 | View |
| Roche | — | partner | Partner that licensed IONIS-FB-LRx and will advance the medicine into a Phase 3 clinical study. | 2022-07-11 | View |
| AstraZeneca | AZN | partner | Strategic collaboration agreement to develop and commercialize eplontersen for the treatment of transthyretin amyloidosi | 2021-12-07 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-23 | Regulation FD; Other Events; Exhibits | View | |
| 2026-10-21 | Regulation FD; Other Events; Exhibits | View | |
| 2026-09-23 | Regulation FD; Other Events; Exhibits | View | |
| 2026-09-04 | Regulation FD; Other Events; Exhibits | View | |
| 2026-09-04 | Regulation FD; Other Events; Exhibits | View | |
| 2026-07-29 | Earnings Release; Exhibits | View | |
| 2026-07-10 | Regulation FD; Exhibits | View | |
| 2026-07-09 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-24 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-12 | Other Events; Exhibits | View | |
| 2026-06-08 | Officer/Director Change; Shareholder Vote; Regulation FD; Exhibits | View | |
| 2026-05-28 | Regulation FD; Other Events; Exhibits | View | |
| 2026-04-29 | Earnings Release; Exhibits | View | |
| 2026-04-21 | Regulation FD; Other Events; Exhibits | View | |
| 2026-03-09 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2026-02-25 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-07 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-17 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
| 2025-11-10 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR